Overview
A Study of the Safety and Efficacy of AGN-214868 in Patients With Postherpetic Neuralgia
Status:
Completed
Completed
Trial end date:
2012-01-01
2012-01-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
This study will evaluate the safety and efficacy of AGN-214868 in patients with postherpetic neuralgia (PHN) - nerve pain.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Allergan
Criteria
Inclusion Criteria:- Persistent postherpetic neuralgia (PHN) with nerve pain present for at least 9 months
after onset of herpes zoster skin rash
Exclusion Criteria:
- Female patients with reproductive potential
- Active herpes zoster skin rash
- Current or anticipated treatment with acupuncture, TNS, or steroids
- Current or anticipated use of topical analgesic agents with PHN
- Treatment with botulinum toxin therapy of any serotype within the prior 12 weeks